Data from a clinical trial involving about 30,000 adults found the vaccine was 90.4 percent effective at preventing COVID-19. However, the study was conducted before the emergence of the highly transmissible delta and omicron variants, the FDA said.
Six participants also developed myocarditis or pericarditis — both types of heart inflammation — after vaccination.
“These events raise the concern for a causal association with this vaccine, similar to the association documented with mRNA COVID-19 vaccines,” the FDA said.
Novavax’s shares fell by more than 20 percent after the FDA released its report.
“We believe there is insufficient evidence to establish a causal relationship,” the company said June 3 in response to the FDA’s report. “We have learned that we can expect to see natural background events of myocarditis in any sufficiently large database.”
An FDA panel of outside experts is slated to meet June 7 to discuss whether to recommend the vaccine for emergency use authorization.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
